- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06009471
A Multicenter Clinical Study of rTMS for Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Aisong Guo
- Phone Number: 15851300188
- Email: guoasg@ntu.edu.cn
Study Locations
-
-
Jiangsu
-
Nantong, Jiangsu, China, 226001
- Recruiting
- rTMS
-
Contact:
- Aisong Guo
- Phone Number: 15851300188
- Email: guoasg@ntu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hoehn-YAHR classification is between 1 and 2;
- Have a primary school education or above and can read the scale used in this study;
- MoCA score between 20 and 24, mild cognitive impairment ;
- Aged between 30 and 80, regardless of gender;
- Voluntarily participate and sign informed consent.
Exclusion Criteria:
- patients with cerebrovascular accident, craniocerebral injury and other diseases affecting muscle tension;
- patients with serious mental disorders and cognitive disorders who cannot cooperate with assessment;
- patients with severe liver, kidney, heart dysfunction and severe physical disorders;
- Implanted devices such as pacemakers are installed inside the body;
- drug-induced Parkinson's syndrome or Parkinson's superposition syndrome;
- Have a history of epilepsy;
- Women during pregnancy and breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control group
All participants were treated with routine treatment in Neurology.
|
Routine treatment in Neurology department, including drug treatment,etc.
|
Experimental: Experimental group
All participants were treated with routine treatment in Neurology and rTMS treatment. rTMS parameters were set to stimulate the site: bilateral primary motor cortex; Stimulus frequency :5Hz; Pulse number: 1000 pulses per day, 500 on the left and 500 on the right; Stimulus intensity :90% resting threshold; Coil: 70mm round coil; Once a day, 30 minutes each time, 5 days a week for 4 weeks |
Add rTMS to routine treatment.
Low frequency rTMS is often used to treat cortical hyperexcitability and high frequency rTMS to treat hypoexcitability
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Unified Parkinson's disease rating Scale (UPDRS)
Time Frame: The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
16 items, each with a score of 0-4, and the score is directly proportional to the severity of PD motor symptoms.
|
The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Montreal Cognitive Assessment Scale (MoCA)
Time Frame: The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Full score of 30 points,>=26 points normal,.
Mild cognitive impairment (MCI) on a scale of 18-26, moderate on a scale of 10-17, and severe on a scale of<10.
|
The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
King's Parkinson's Pain Assessment (KPPS)
Time Frame: The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Evaluate the pain degree and quality of life of patients with Parkinson's disease, including 14 items in 7 aspects, including skeletal muscle pain, Chronic pain, symptom fluctuation related pain, nocturnal pain, orofacial pain, distention pain, and nerve root pain.
Each score is expressed as pain severity (0-3 levels) multiplied by frequency (0-4 levels), that is, 0-12 points.
The total score is 168 points.
The higher the score, the more severe the pain.
|
The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
PD Sleep Scale (PDSS)
Time Frame: The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Evaluate the patient's sleep status, with a total of 15 items on the scale.
Each item is scored on a scale of 0-10 points, with a lower score indicating poorer sleep status.
|
The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Activities of daily living Assessment - Barthel
Time Frame: The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
The total score of the index is 100 points, and the higher the score, the better the self-care ability and the less dependence.
Those scoring above 60 can basically complete basic Activities of daily living, 59-41 need some help to complete, 40-21 need a lot of help.
Those who score below 20 are in complete need of help and cannot take care of themselves.
|
The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Depression Scale (HAMD)
Time Frame: The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Evaluate depressive status, including 14 5-level scoring items (0-4 points) and 10 3-level scoring items (0-2 points).
Score<8, no depression; 8 to 35 points, may be mild or moderate depression 35 points, may be severe depression.
|
The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Hamilton Anxiety Scale (HAMA)
Time Frame: The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Include 14 projects.
All items of HAMA adopt a 5-level scoring method of 0~4 points, and the criteria of each level are: (0) is Asymptomatic; (1) Light; (2) Moderate; (3) Heavy; (4) Extremely heavy.
The total score of HAMA can better reflect the severity of anxiety symptoms.
The total score can be used to evaluate the severity of anxiety symptoms and evaluate the effectiveness of various drugs and psychological interventions in patients with anxiety and depression disorders.
According to the data provided by the collaborative group of the Chinese scale, if the total score exceeds 29 points, it may be severe anxiety; Above 21 points, there must be obvious anxiety; If the score exceeds 14, there must be anxiety; If the score exceeds 7, there may be anxiety; If the score is less than 7, there are no symptoms of anxiety.
Generally speaking, the total score of HAMA is higher than 14 points, indicating clinically significant anxiety symptoms for the evaluated subject.
|
The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCYJ-B06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on Routine treatment in Neurology
-
Fundación Cardiovascular de ColombiaInstituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)RecruitingStroke | Compliance, Patient | Compliance, Treatment | Compliance, MedicationColombia
-
University Hospital, BrestCompletedChildren | High Intellectual PotentialFrance
-
GlaxoSmithKlineMacroStatCompleted
-
University of LeipzigRecruiting
-
University of AlcalaUnknown
-
Ferring PharmaceuticalsCompleted
-
Shanghai 6th People's HospitalRecruitingLung Cancer | Bone Metastases | Single Cell Sequencing TechnologyChina
-
University of OsloRecruitingIntellectual Disability | Autism Spectrum Disorder | Communication, NonverbalNorway
-
Peking University Third HospitalNot yet recruitingAcute Myocardial Infarction
-
Capital Medical UniversityRecruiting